You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (±)-trans-ACPD
(±)-trans-ACPD is an equimolecular mixture of (1S,3R)- and (1R,3S)-ACPD. Selective agonist for metabotropic glutamate receptors; active at both group I and group II mGlu receptors (EC50 values are 2, 15, 23 and ~800 μM at mGluR2, mGluR1, mGluR5 and mGluR4 respectively).
Technical Data for (±)-trans-ACPD
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (±)-trans-ACPD
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||5 with gentle warming|
Preparing Stock Solutions for (±)-trans-ACPD
The following data is based on the product molecular weight 173.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||11.55 mL||57.75 mL||115.49 mL|
|2.5 mM||2.31 mL||11.55 mL||23.1 mL|
|5 mM||1.15 mL||5.77 mL||11.55 mL|
|25 mM||0.23 mL||1.15 mL||2.31 mL|
References for (±)-trans-ACPD
References are publications that support the biological activity of the product.
Conti et al (2002) Synthesis and pharmacology of 3-hydroxy-Δ2-isoxazoline-cyclopentance analogues of glutamic acid Farmaco 57 889 PMID: 12484537
Knopfel et al (1995) Metabotropic glutamate receptors: novel targets for drug development. J.Med.Chem. 38 1417 PMID: 7738999
Nakanishi (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258 597 PMID: 1329206
Pin and Duvoisin (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 1 PMID: 7623957
If you know of a relevant reference for (±)-trans-ACPD, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: trans-ACPD, trans-ACPD supplier, Group, II, group, I, mGlur, agonists, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, tacpd, trans-acpd, (Metabotropic), 0187, Tocris Bioscience
7 Citations for (±)-trans-ACPD
Citations are publications that use Tocris products. Selected citations for (±)-trans-ACPD include:
Coulon et al (2011) Activity Modes in Thalamocortical Relay Neurons are Modulated by G(q)/G(11) Family G-proteins - Serotonergic and Glutamatergic Signaling. Front Cell Neurosci 4 132 PMID: 21267426
Rojas et al (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol Pharmacol 83 106 PMID: 23066089
Newman (2005) Calcium increases in retinal glial cells evoked by light-induced neuronal activity. J Neurosci 25 5502 PMID: 15944378
Ying and Goldstein (2005) PropF. suppresses synaptic responsiveness of somatosensory relay neurons to excitatory input by potentiating GABA(A) receptor chloride channels. Mol Pain 1 2 PMID: 15813991
Young and Sun (2007) Long-term modifications in the strength of excitatory associative inputs in the piriform cortex. Chem Senses 32 783 PMID: 17634388
Fujino and Oertel (2003) Bidirectional synaptic plasticity in the cerebellum-like mammalian dorsal cochlear nucleus. Proc Natl Acad Sci U S A 100 265 PMID: 12486245
Nishi et al (2003) Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc Natl Acad Sci U S A 100 1322 PMID: 12538871
Do you know of a great paper that uses (±)-trans-ACPD from Tocris? Please let us know.
Reviews for (±)-trans-ACPD
Average Rating: 5 (Based on 1 Review.)
Have you used (±)-trans-ACPD?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
trans-ACPD is mGluR agonist (Group I and II). We used at 100 microM in rat brain slices. It increases intracellular Ca2+ in astrocytes.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.